Last reviewed · How we verify
Psyquil (TRIFLUPROMAZINE)
Psyquil (generic name: TRIFLUPROMAZINE) is a drug. It is currently FDA-approved (first approved 1957) for Nausea, Nausea and vomiting, Psychotic disorder.
Psyquil is a small molecule that acts as a dopamine D2 receptor antagonist. It is classified as an antagonist and has been known by various synonyms, including Triflupromazine.
At a glance
| Generic name | TRIFLUPROMAZINE |
|---|---|
| Target | Multidrug resistance protein 1, 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
- Nausea
- Nausea and vomiting
- Psychotic disorder
- Vomiting
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Psyquil CI brief — competitive landscape report
- Psyquil updates RSS · CI watch RSS
Frequently asked questions about Psyquil
What is Psyquil?
What is Psyquil used for?
What is the generic name of Psyquil?
When was Psyquil approved?
What development phase is Psyquil in?
What does Psyquil target?
Related
- Target: All drugs targeting Multidrug resistance protein 1, 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor
- Therapeutic area: All drugs in Other
- Indication: Drugs for Nausea
- Indication: Drugs for Nausea and vomiting
- Indication: Drugs for Psychotic disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing